ALNY compared with ARGX: revenue, margins and what each company keeps, and the suppliers and customers both name

ALNYAlnylam Pharmaceuticals, Inc.

Mkt capRevenueRevenue

ARGXArgenx SE

Mkt capRevenueRevenue

Compare

ALNYAlnylam Pharmaceuticals, Inc.

ARGXArgenx SE

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ARGX: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ALNY 14

BXBlackstonesupplier

REGNRegeneroncustomer

AAgilentsupplier

VEEVVeeva Systemssupplier

10 more · ALNY chain ›

Shared 0

No shared counterparties.

Only ARGX 3

ABBVAbbViecustomer

HALOHalozyme Therapeuticssupplier

—AgomAb Therapeuticsunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

ALNY, solidARGX, dashed

ALNYAlnylam Pharmaceuticals, Inc.

164.89▼−5.24%· post 165.53

Mkt cap$22.1BRevenue$1.5BQ3 FY26Revenue$3.7BFY25

ARGXArgenx SE

893.85▼−0.45%· post 895.00

ClosedOct 30 '26

Mkt cap$55.3BRevenue—Revenue—

Compare

ClosedOct 30 '26

ALNYAlnylam Pharmaceuticals, Inc.

ARGXArgenx SE

164.89▼−5.24%post 165.53

Price

893.85▼−0.45%post 895.00

$22.1B

Mkt cap

$55.3B

Q3 FY26$1.5B

Revenue

—

FY25$3.7B

Revenue

—

ALNY164.89▼−5.24%vsARGX893.85▼−0.45%ClosedOct 30 '26